Voyager Therapeutics, Inc. (VYGR) News
Filter VYGR News Items
VYGR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VYGR News Highlights
- For VYGR, its 30 day story count is now at 3.
- Over the past 11 days, the trend for VYGR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about VYGR are DRUG, GENE and DEC.
Latest VYGR News From Around the Web
Below are the latest news stories about VOYAGER THERAPEUTICS INC that investors may wish to consider to help them evaluate VYGR as an investment opportunity.
7 Undervalued Biotech Stocks That are Flying Under the Clinical RadarWith so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. |
12 Best Healthcare Stocks For the Long-TermIn this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare industry is one of the biggest industries in the world. […] |
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program- IND filing expected in mid-2025 -LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program. The Company anticipates filing an investigational new drug (IND) application with the Food and Drug Admini |
Voyager Therapeutics (NASDAQ:VYGR) shareholders have endured a 43% loss from investing in the stock five years agoFor many, the main point of investing is to generate higher returns than the overall market. But even the best stock... |
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Earnings Call TranscriptVoyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Earnings Call Transcript November 6, 2023 Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were $-0.58. Operator: Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2023 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session […] |
Voyager Therapeutics Inc (VYGR) Reports Q3 2023 Financial ResultsCompany's net loss stands at $25.9 million, collaboration revenue drops to $4.6 million |
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conference call at 4:30 p.m. ET today - LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2023 financia |
Will Weakness in Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Prove Temporary Given Strong Fundamentals?Voyager Therapeutics (NASDAQ:VYGR) has had a rough three months with its share price down 27%. However, a closer look... |
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and WebcastCAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on Monday, November 6, 2023. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results. To participate via telephone and join the call live, |
Voyager Therapeutics to Present at the Chardan Genetic Medicines ConferenceCAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Chardan 7th Annual Genetic Medicines Conference in New York, NY, on October 2, 2023, at 5:30 p.m. ET. A webcast of the presentation may be accessed from the Investors section of Voyager’s website at ir.voyag |